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Figure. Neutrophil engraftment by dominant unit infused viable CD34+ cell dose 105/kg
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Background: High-dose chemotherapy followed by autolo-
gous stem cell transplantation (ASCT) for multiple myeloma
(MM) offers a unique opportunity for the early introduction of
consolidative immunotherapy to improve patient outcomes.
Post-transplant reconstitution of immune cell subsets, how-
ever, occurs with disparate kinetics that can affect efﬁcacy. A
comprehensive understanding of the immunologic milieu is
therefore essential to the rational development of immuno-
therapeutic interventions after ASCT, where relapse remains
the primary cause of treatment failure.
Methods: Immune reconstitution in 40 MM patients un-
dergoing ASCT was evaluated for one year. Peripheral blood
Figure 1. T cell reconstitution in MM patients after high-dose chemotherapy
and autologous stem cell transplantations (ASCT).
(A) T cell composition: Peripheral blood was analyzed by ﬂow cytometry for
total CD3+, CD3+, CD4+ and CD3+ CD8+ T cells at the indicated time points (d +
11, 30, 90, 180, and 365) after ASCT and compared with pre-ASCT values (pre),
Total CD3+ cells are plotted against the LEFT Y axis. CD4+ and CD8+ cells are
Figure 2. Natural killer (NK) cell reconstitution in MM patients after high-
dose chemotherapy and autologous stem cell transplantation (ASCT). Periph-
eral blood was analyzed by ﬂow cytometry for NK cells (CD3negCD56+) at the
indicated time points (d +11, 30, 90, 180, and 365) after ASCT and compared
with pre-ASCT values (pre). Pooled data (mean  SD) from 40 pts are shown.
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+90, +180, and +365 after ASCT. Mononuclear cells were
analyzed by ﬂow cytometry for phenotypic assessment of
lymphocyte subset composition. Functional assessment of T
cell responsiveness was assayed as follows: Monocyte-
derived dendritic cells (moDCs) generated from peripheral
blood were electroporated with WT1 mRNA and then added
in serial doses to triplicate microwells containing autologous
T cells obtained pre- and post-ASCT (d +11, 30, 90), supple-
mented with IL15 x 7d. Antigen-speciﬁc target cell lysis by
cytotoxic T lymphocytes (CTLs) induced by moDCs was
evaluated using a ﬂow cytometry-based assay.
Results: Total CD3+ T cell levels return to normal by d +30
(Fig 1A). The recovery of CD8+ T cells, however, precedes the
recovery CD4+ T cells, resulting in an inverted CD4/CD8 ratio
(Fig 1A). CD4+CD45RO+ memory T cell recovery occurs by
d +11, whereas CD4+CD45RA+ naïve T cells remain low at one
year (Fig 1B). Immune-suppressive CD3+CD4+CD25bright
CD127neg regulatory T cells (Tregs) are reduced early post-
nadir as CD8+ T cell recovery occurs, resulting in a markedly
reduced Treg:CD8+ effector T cell ratio (Fig 1C). T cells uni-
formly express the negative regulatorymolecules, CTLA4 and
PD1, after ASCT (data not shown). CD3negCD56+ natural killer
cells exhibit rapid and sustained recovery after ASCT (Fig 2).
Robust antigen-speciﬁc CTLs are induced by autologous
mRNA-electroporated moDCs after only 7 days’ stimulation
of T cells in vitro, demonstrating that active cellular immune
responses can be elicited as early as d +11 (Fig 3). Subgroup
analysis of patients based on pre- and post-ASCT disease
status (i.e., PR vs VGPR vs CR) revealed no signiﬁcantplotted against the RIGHT Y axis.
(B) Naïve and memory CD4+ T cells: Peripheral blood was analyzed by ﬂow
cytometry for naïve (CD4+ CD45RA+) and memory (CD4+ CD45RO+) T cells at
the indicated time points (d +11, 30, 90, 180, 365) after ASCT and compared
with pre-ASCT values (pre). Pooled data (mean  SD) from 40 pts are shown.
(C) Treg:CD8+ effector ratio: Peripheral blood was analyzed by ﬂow cytom-
etry for Tregs (CD3+ CD4+ CD25bright CD127neg) and CD8+ T cells at the indi-
cated time points before (pre) and after (d+11, 30, 90, 180, and 365) ASCT to
calculate Treg/CD8+ affector ratios. Pooled data (mean  SD) from 40 pts are
shown.
HI HSCT (%) MR HSCT (%)
Number 29 23
Age (range) 49 (21-65) 49 (27-64)
Sex (M/F) 19/10 17/6
Median CD34 cells (x 106/kg) 4.7 4.32
Disease
AML/MDS 16 (55) 11 (48)
ALL 11 (38) 5 (22)
NHL 2 (7) 7 (30)
Conditioning
MA 29 (100) 21 (91)
RIC 0 2 (9)
Outcomes:
Median ANC recovery -days 11 11
Median Platelet recovery- days 17 18
aGVHD III-IV 3 (10) 1 (4)
cGVHD 5 (12) 1 (4)
CMV Reactivation 10 (35) 4 (17)
Deaths 5 (17) 5 (22)
Cause of Death:
Infection 0 0
Relapse 4 (14) 4 (17)
Toxicity 1 (3) 1 (4)
GVHD 0 0
Figure 3. mRNA-electroporated, CDs from MM patients induce autologous
antigen-speciﬁc CTLs after autologous stem cell transplantation (ASCT).
Cytokine-generated, moDCs derived form peripheral blood were eclectropo-
rated with WT1 mRNA, terminally matured by a combination of inﬂammatory
cytokines, and then added in serial doses to triplicate micorwells containing 1
 102 autologous T cells obtained pre- and post-ASCT (d +11, 30, and 90) and
cultured with IL 15 for 7 days, Antigen-speciﬁc target cell lysis by CTLs stim-
ulated by WT1 mRNA-electroporated moDCs was evaluated using a ﬂow
cytometry-based assay.
Target cells for were 697 cells (HLA-A+0201+, WT1+ cell line). Speciﬁc lysis is
plotted against the y-axis comparing the lysis activity of T cells stimulated by
mRNA-electroporated moDCs at the indicated time points (d +11, 30, and 90)
after ASCT and compared with pre-ASCT value (pre). Data points ate the av-
erages  SEM of triplicate means from one experiment.
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groups.
Conclusion: In addition to decreased disease burden, a
favorable shift in Treg to effector T cell ratios characterizes
the early post-transplant period. This provides a critical
window for immunotherapeutic modalities like vaccines and
checkpoint blockade agents to induce antitumor immunity.60
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Haploidentical (HI) HSCT enfranchises patients (pts) who
have no HLA matched donor. In the 2-step approach to HI
HSCT, a large ﬁxed dose of allogeneic T cells are infused after
conditioning, followed 2 days later by cyclophosphamide
(CY) to induce bidirectional tolerance. A CD34 selected stem
cell product is infused after CY. CYeradicates only activated T
cells, supporting post HSCT immune reconstitution (IR) and
low rates of GVHD. Given the favorable results with this
approach in HI HSCT, we applied the regimen to MR HSCT.
Delivering a ﬁxed dose of donor T cells within the same
2 step regimen provides a level baseline from which to
evaluate whether HI HSCT is inherently inferior to MR HSCT.
Thus, we compared IR and clinical outcomes of patients
undergoing HI HSCT versus MR HSCT using this approach.Flow cytometric assessment of T-cell subsets was used to
measure IR at day (D) +28 and +90 in pts undergoing HI and
MR HSCT. Pts were evaluable for IR analysis if they had full
donor chimerism, had no evidence of disease, and were fully
